[1]孙 辉,陈英耀,何露洋,等.医生治疗非小细胞肺癌的选择偏好研究[J].卫生经济研究,2018,(09):10-13.
　SUN Hui,CHEN Ying-yao,HE Lu-yang,et al.Doctor's Choice Preference for Non-small Cell Lung Cancer Treatment[J].Journal Press of Health Economics Research,2018,(09):10-13.
点击复制

医生治疗非小细胞肺癌的选择偏好研究

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2018年09期
页码:
10-13
栏目:
卫生技术评估
出版日期:
2018-09-04

文章信息/Info

Title:
Doctor's Choice Preference for Non-small Cell Lung Cancer Treatment
作者:
孙 辉1; 陈英耀1; 何露洋1; 覃肖潇1; 李 达1; 王弓茹1; 张 晨1
1.复旦大学公共卫生学院，卫生部卫生技术评估重点实验室，世界卫生组织卫生技术评估与管理合作中心，上海 200032
Author(s):
SUN Hui; CHEN Ying-yao; HE Lu-yang; TAN Xiao-xiao; LI Da; WANG Gong-ru; ZHANG Chen
Key Laboratory of Health Technology Assessment of the Ministry of Health，School of Public Health，Fudan University，World Health Organization Center for Health Technology Assessment and Management，Shanghai 200032，China
关键词:
非小细胞肺癌; 医生偏好; 离散选择实验
Keywords:
non-small cell lung cancer; doctor's preference; discrete selection experiment
分类号:
R19
文献标志码:
A
摘要:
运用离散选择实验，分析医生对非小细胞肺癌不同治疗结局的权衡偏好，为促进医患共同参与医疗决策提供参考。结果显示，不同治疗结局属性影响医生处方偏好的权重和相对重要程度依次为：无进展生存期、重度不良反应发生风险、疾病控制率、轻度不良反应发生风险、给药方式。可见，疗效是医生治疗非小细胞肺癌最先考虑和最为看重的，其次是考虑控制药物毒性，给药方式对医生选择治疗方案的影响程度较低。
Abstract:
Discrete selection experiments were used to analyze the doctor's trade-off preference for different treatment outcomes of non-small cell lung cancer，and to provide reference for promoting the full participation of doctors and patients in medical decision-making. The results showed that the weight and relative importance of different treatment outcome attributes affecting doctors' prescription preferences were：progression-free survival，risk of severe adverse reactions，disease control rate，risk of mild adverse reactions，and method of drug administration. It can be seen that the curative effect is the first and most important consideration for doctors to treat non-small cell lung cancer. Secondly，it is also important to control the toxicity of the drug，and the method of drug administration has a lower influence on the doctor's choice of treatment plan.

参考文献/References:

[1] Muehlbacher AC, Nuebling M. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma [J] . EUROPEAN JOURNAL OF HEALTH ECONOMICS,2011, 12: 193-203.
[2] Berchi C, Dupuis J, Launoy G. The reasons of general practitioners for promoting colorectal cancer mass screening in France[J]. The European journal of health economics : HEPAC : health economics in prevention and care,2006, 7: 91-98.
[3] Ng AK, Li S, Neuberg D, et al. Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians[J]. ANNALS OF ONCOLOGY,2004, 15: 261-269.
[4] Ettinger DS GSHA. Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settings[J]. Support Care Cancer,2009,19: 405-411.
[5] Benjamin L, Cotte F, Philippe C, et al. Physicians' preferences for prescribing oral and intravenous anticancer drugs: A Discrete Choice Experiment[J]. EUROPEAN JOURNAL OF CANCER,2012,48: 912-920.
[6] Wouters H, Van Dijk L, Van Geffen ECG,et al.Stiggelbout AM. Do the benefits of statins outweigh their drawbacks? Assessing patients' trade-off preferences with conjoint analysis[J]. INTERNATIONAL JOURNAL OF CARDIOLOGY,2014,176: 1220-1222.

相似文献/References:

[1]田梦媛,殷 潇,张欲晓,等.吉非替尼治疗晚期非小细胞肺癌的医保预算影响分析[J].卫生经济研究,2016,(12):25.
[2]孙 辉,陈英耀,任绍聪,等.非小细胞肺癌患者疾病治疗偏好与意愿支付研究[J].卫生经济研究,2018,(09):6.
　SUN Hui,CHEN Ying-yao,REN Shao-cong,et al.Study on Disease Treatment Preference and Willingness Payment in Patients with Non-small Cell Lung Cancer[J].Journal Press of Health Economics Research,2018,(09):6.
[3]丁海樱,孔思思,孙 娇,等.盐酸安罗替尼用于晚期非小细胞肺癌治疗的成本效用分析[J].卫生经济研究,2020,(05):19.
　DING Hai-ying,KONG Si-si,SUN Jiao,et al.Cost-effectiveness Analysis of Anlotinib Hydrochloride for Treatment of Advanced Non-Small Cell Lung Cancer[J].Journal Press of Health Economics Research,2020,(09):19.
[4]汤雅倩,赵明烨,唐文熙.信迪利单抗对比卡瑞利珠单抗一线治疗 晚期非鳞状非小细胞肺癌的经济学评价[J].卫生经济研究,2023,40(2):34.
　TANG Yaqian,ZHAO Mingye,TANG Wenxi.Pharmacoeconomic Evaluation of Sintilimab Versus Camrelizumab in the First-Line Treatment of Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer in China[J].Journal Press of Health Economics Research,2023,40(09):34.

更新日期/Last Update: 2018-09-05